Very low frequency of rejection due to HLA-(A+)B+DQ matching.
Christiaans
M H
MH
Department of Internal Medicine, University Hospital, Maastricht, The Netherlands.
van den Berg-Loonen
P M
PM
Nieman
F H
FH
van Hooff
J P
JP
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002102:Cadaver; D016572:Cyclosporine / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D015234:HLA-A Antigens / Q000276:immunology*; D015235:HLA-B Antigens / Q000276:immunology*; D015236:HLA-C Antigens / Q000276:immunology; D006683:HLA-DQ Antigens / Q000276:immunology*; D006684:HLA-DR Antigens / Q000276:immunology; D006650:Histocompatibility Testing / Q000379:methods*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D011239:Prednisolone / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate
D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; D016572:Cyclosporine; D011239:Prednisolone